Matched placebo for test product clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled, parallel-group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis
This study is testing a new medicine, itepekimab, for people with bronchiectasis. It aims to see if the medicine can reduce flare-ups of their condition and if it's safe to use. Half the people will get the new medicine, and half will get a dummy medicine.
For: BronchiectasisItaly · Czechia · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) (AERIFY-1)
This study is testing a new medicine, itepekimab, for people with moderate to severe COPD. We want to see if it can reduce flare-ups of their breathing problems. It's a large study where some people get the new medicine and others get a dummy medicine, to compare the effects.
For: Chronic Obstructive Pulmonary DiseaseRomania · Slovakia · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
This study is looking into a new treatment called itepekimab for people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It will compare the new drug to a dummy treatment to see if it helps reduce flare-ups of COPD and improves lung function in former smokers.
For: Chronic Obstructive Pulmonary DiseaseCzechia · Germany · Poland - AuthorisedTherapeutic confirmatory (Phase III)
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine called Duvakitug for people with moderate to severe ulcerative colitis. It aims to see if Duvakitug can help keep symptoms in remission (controlled) and improve quality of life compared to a dummy medicine.
For: Immune system diseasesSlovakia · Germany · Austria - AuthorisedTherapeutic confirmatory (Phase III)
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
This study is looking at a new medicine called duvakitug for people with moderate to severe Crohn's disease. Researchers want to see if it helps keep the disease under control and is safe to use. It's a phase 3 study, meaning many people will take part.
For: Immune system diseasesSpain · Czechia · Lithuania